2 December 2022 - Merck, a leading science and technology company, and the Pediatric Praziquantel Consortium, today announced that the EMA has validated for review the application for arpraziquantel for the treatment of schistosomiasis in preschool-aged children (3 months to 6 years of age).
The application was submitted by Merck Serono on behalf of the Consortium for a scientific opinion by EMA under the EU-M4all procedure for high priority medicines for human use intended for markets outside the European Union.